Benchmark Reiterates Buy Rating on Neogenomics (NEO)

September 24, 2024 7:05 AM UTC Send to a Friend
Benchmark analyst Bruce Jackson reiterated a Buy rating and $18.00 price target on Neogenomics (NASDAQ: NEO).The analyst commented: "Last night ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login